FTC May Be Hampered In Pursuing Actions Against Pharma In Wake Of Supreme Court Ruling
Executive Summary
High court’s decision that FTC lacks authority to seek monetary recovery in litigation is boon for drug makers who have been subject to hefty payouts in reverse settlement and other cases brought by the commission.
You may also be interested in...
FTC Aims At Deceptive Endorsements: Beauty, Health Firms Can Assure They're Not Targets
US FTC sends notices to more than 700 companies about penalties they will face if they use deceptive endorsements and testimonials to promote their products. Industry experts discuss impact of surprising action and cautions to take in teaming up with influencers.
Pharma Companies Must Assure Their ‘House Is In Order’ As FTC Takes Aim At Deceptive Endorsements
US FTC sends notices to more than 700 companies about penalties they will face if they use deceptive endorsements and testimonials to promote their products. Industry experts discuss impact of surprising action and cautions to take in teaming up with influencers.
US FTC Removing ‘Handcuffs’ To Pursue Pharma Companies, PBMs For Antitrust Violations
Agency staff has more freedom to launch investigations under resolutions approved at Commission’s first meeting under new chair. Mergers and rebate walls expected to be major priorities.